GlaxoSmithKline’s ViiV Healthcare launches new study of HIV regimen

GlaxoSmithKline has announced that its ViiV Healthcare business has launched a new phase III clinical trial of a promising treatment for people with HIV-1 infections.

The phase III study will assess a two-drug regimen of ViiV Healthcare's long-acting injectable cabotegravir and Janssen's rilpivirine among virally suppressed adults with HIV-1 infection.

Entitled ATLAS-2M, the study is designed to demonstrate the non-inferior antiviral activity, at 48 weeks of treatment, of this regimen when administered every eight weeks, compared with cabotegravir and rilpivirine administered every four weeks.

It will also assess patient satisfaction and provide comparative data on antiviral activity, pharmacokinetics, safety and tolerability for up to 96 weeks. Initial results from this study are anticipated in 2019.

This represents the third phase III trial of this regimen to be launched, following the ATLAS and FLAIR studies. Results from these trials will be published next year.

John Pottage, chief scientific and medical officer at ViiV Healthcare, said: "We have a patient-centred approach to innovation that seeks to transform how HIV is treated. Our focus on two-drug regimens is key to this strategy."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.